Common side effects (from clinical trial data): Nausea affects roughly 44% of users Diarrhea 30% Vomiting 24% Constipation 24% Abdominal pain 20% These are the main reasons most people stop taking these drugs
Any of our patients can bring their sharps to our office for disposal
Over a median follow-up of 49.5 months, oral semaglutide reduced the risk of MACE by 14% compared to placebo (HR 0.86
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
Purity, sterility, and accurate dosing are major unknowns
Yes, patients who are eligible for treatment of type 2 diabetes with Rybelsus may be able to access it through the NHS, though this is dependent on local policies and protocols